Cadwell Industries, Inc. has announced a strategic investment in Seer Medical to enhance home-based epilepsy diagnostics, aiming to integrate their innovative technologies for improved patient care.

Information on the Target

Cadwell Industries, Inc., a prominent global player in neurodiagnostic, neuromonitoring, and sleep solutions, has made a strategic investment in Seer Medical, based in Melbourne, Australia. Seer Medical, founded in 2017, focuses on home-based diagnostics for epilepsy, leveraging advanced cloud, web, and AI technologies. Their flagship product, Seer Home, offers long-term video electroencephalography (EEG) monitoring, allowing for the assessment of the brain's electrical activity without requiring hospitalization. This innovation is crucial as epilepsy is a common chronic neurological condition, affecting over 50 million individuals worldwide.

This investment enhances Cadwell’s capabilities by integrating Seer Medical’s revolutionary home EEG technology with its established EEG product line. This collaboration aims to deliver superior diagnostic and treatment solutions for clinical, ambulatory, and hospital settings dedicated to epilepsy care.

Industry Overview in Australia

The epilepsy care landscape in Australia is evolving, particularly with the growing demand for innovative diagnostic tools that prioritize patient comfort and accessi